LENALIDOMIDE, A THALIDOMIDE ANALOGUE, IS AN IMMUNOMODULATORY AGENT WITH ANTIANGIOGENIC AND ANTINEOPLASTIC PROPERTIES, INDICATED FOR THE TREATMENT OF PATIENTS WITH TRANSFUSION-DEPENDENT ANEMIA DUE TO LOW- OR INTERMEDIATE RISK MYELODYSPLASTIC SYNDROMES ASSOCIATED WITH A DELETION 5Q CYTOGENETIC ABNORMALITY WITH OR WITHOUT ADDITIONAL CYTOGENETIC ABNORMALITIES.
OR
IN COMBINATION WITH DEXAMETHASONE IS INDICATED FOR THE TREATMENT OF MULTIPLE MYELOMA PATIENTS WHO HAVE RECEIVED AT LEAST ONE PRIOR THERAPY.
THE RECOMMENDED INITIAL DOSE IS 10 MG DAILY BY MOUTH.DOSAGE IS ADJUSTED ACCORDING TO HAEMATOLOGICAL TOXICITY.
MYELODYSPLASTIC SYNDROMES:
THE RECOMMENDED STARTING DOSE IS 10 MG DAILY
MULTIPLE MYELOMA
THE RECOMMENDED STARTING DOSE OF REVLIMID® (LENALIDOMIDE) IS 25 MG/DAY WITH WATER ORALLY ADMINISTERED AS A SINGLE 25 MG CAPSULE ON DAYS 1-21 OF REPEATED 28-DAY CYCLES. PATIENTS SHOULD NOT BREAK, CHEW OR OPEN THE CAPSULES. THE RECOMMENDED DOSE OF DEXAMETHASONE IS 40 MG/DAY ON DAYS 1-4, 9-12, AND 17-20 OF EACH 28-DAY CYCLE FOR THE FIRST 4 CYCLES OF THERAPY AND THEN 40 MG/DAY ORALLY ON DAYS 1-4 EVERY 28 DAYS. DOSING IS CONTINUED OR MODIFIED BASED UPON CLINICAL AND LABORATORY FINDINGS.